Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Assessment of accuracy of sentinel node biopsy, defined as the false negative rate.
Current practice in patients with Clinical Stage I (CS I) testicular germ cell tumour is active surveillance after orchiectomy, with relapses occurring in 15-20% of patients. The majority of relapses occur in the lymph nodes as lymphogenic spread is the dominant route of dissemination. A sentinel node procedure, in which the sentinel lymph node is resected and pathologically examined, could be more reliable to identify patients who are likely to relapse.
Early identification of patients with micro-metastases in the sentinel node makes it possible to treat these patients at the earliest possible moment. Absence of metastases could lead in the future to a less intensive follow up protocol than the present one.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| sentinel node procedure | a robot-assisted laparoscopic sentinel node procedure. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| sentinel node procedure | Procedure | a robot-assisted laparoscopic sentinel node procedure to detect occult lymph node metastasis |
|
| Measure | Description | Time Frame |
|---|---|---|
| identify patients witha low risk of cancer recurrenceincluded in current active surveillance protocols. | identify patients who have such a low risk of cancer recurrence that it is not necessary anymore to be included in current active surveillance protocols by removing the sentinal lymph node to check for occult metastasis | surgery 1 day, follow up 5 years |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
testical germ cell tumors
Not provided
Patients suspected of testicular germ cell tumour
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Joost Blok, MD | Contact | 0031 20 5129111 | j.blok@nki.nl |
| Name | Affiliation | Role |
|---|---|---|
| Simon Horenblas, MD, PhD | NKI-AvL | Principal Investigator |
Not provided
Not provided
| ID | Term |
|---|---|
| C563236 | Testicular Germ Cell Tumor |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided